Sponsored Links
| Cytori Reports Sustained Benefits At 18 Months In Cardiac Cell Therapy Heart Attack Trial |
 |
 |
 |
| Medical News - Heart Disease | |||
|
Cytori Therapeutics (NASDAQ: CYTX) is reporting 18 month outcomes from its APOLLO trial for Acute Myocardial Infarction (AMI)... Read more: Heart Disease News From Medical News Today
|